MIMEDX, Organogenesis Inc., Smith+Nephew are Dominating the Global Amniotic Product Market

Global Amniotic Product Market is expected to grow with the CAGR of 8.6% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-amniotic-products-market

Global amniotic product market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenario.

The major players dealing in the global amniotic product market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

MIMEDX is dominating player in the global amniotic product market. The other key players existing in the market includes are MIMEDX, Smith+Nephew, Organogenesis Inc., Integra LifeSciences, Stryker, APPLIED BIOLOGICS, Katena Products. Inc., Lucina BioSciences, Next Biosciences, Skye Biologics Holdings, LLC., Surgenex, LLC., Ventris Medical, LLC., VIVEX Biologics, Inc., StimLabs LLC., LifeCell International Pvt. Ltd., NuVision Biotherapies Ltd., Genesis Biologics, Amnio Technology, LLC., AMNICELL Corporation, LTD. AlloSource among others    

Amniotic Products MarketMIMEDX

MIMEDX was founded in 1985 and is headquartered in Georgia, U.S. The company focuses on distributing human placental-based tissue allografts for multiple sectors of healthcare, including wound care, burn, and various surgical applications. The company offers range of product categories including Advanced Wound Solutions and Advanced Surgical Solutions in which market focused category fall under Advanced Surgical Solutions. The company is taking strategic initiatives to increase its portfolio.

  • In March 2020, MiMedx announced that the U.S. Food and Drug Administration (FDA) has granted MiMedx's micronized amniotic tissue, AmnioFix Injectable, the Regenerative Medicine Advanced Therapy (RMAT) designation for use in the treatment of Osteoarthritis of the knee. The FDA also confirmed its determination that MiMedx Allogeneic Micronized Dehydrated Human Amnion/Chorion Membrane (micronized dHACM) for the treatment of Osteoarthritis of the knee meets the criteria for RMAT designation. This launch by MiMedx contributed to the unmet medical needs for this condition.

The company has global presence in North America.

Organogenesis Inc.,

Organogenesis Inc. was founded in 1985 and is headquartered in Massachusetts, U.S. The company is focused on empowering healing through the development, manufacturing and sale of products for the advanced wound care, and surgical and sports medicine markets. The company offers range of product categories Advanced Wound Care, Surgical & Sports Medicinein which market focused category falls under Advanced Wound Care. The company is taking strategic initiatives to increase its product portfolio.

  • In November 2021, Organogenesis Inc. announced that its Apligraf wound-healing technology has become the first transplant product in Switzerland to receive marketing authorization from Swissmedic for the treatment of venous leg ulcers (VLU) and diabetic foot ulcers (DFU). This product launch helped the company to enhance its wound-healing technology.

The company has global presence in North America, Asia - Pacific.

Smith+Nephew

Smith+Nephew was founded in 1937 and is headquartered in Herefordshire, U.K. The company is focused on providing a comprehensive set of products to meet broad and complex clinical needs, to help healthcare professionals get lower human and economic consequences of wounds.The company has following business segments - Advanced Wound Management, Orthopaedic Reconstruction, Sports Medicine and ENT, in which the market focused segment is Advanced Wound Management. The company offers product categories including Wound Management, Ear, Nose and Throat, Extremities and Limb Restoration, Orthopaedic Reconstruction, Sports Medicine, Trauma Fixation in which the market focused category falls under Wound Management.The company is increasing its product portfolio such as:

  • In September 2020, Smith & Nephew’s subsidiary Osiris Therapeutics, Inc. announced launch of GrafixPL PRIM, a human placental membrane that can be stored at ambient temperatures. The structural matrix, growth factors, and cell viability of GrafixPL PRIME is equivalent to those of Grafix, a cryopreserved placental membrane, but without the constraints of ultra-low temperature storage. This launch helped the company to meet the complex clinical needs of patients and doctors.

The company has global presence in the South America, North America, Europe , Asia- Pacific, Middle East and Africa.The company has many subsidiaries such as A2 Surgical (France), Blue Sky Medical Group Inc (USA), Endocare GmbH (Germany), Exogen, Inc (USA), Healicoil Inc. (USA), Hipco Inc (USA), ICEMBE Medical (pty) Ltd (South Africa), Oratec Interventions, Inc (USA) among others.